Tag Archives: ACAD
Oppenheimer Remains a Hold on ACADIA Pharmaceuticals (ACAD)
In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $48.00. The company’s shares closed last Friday at $52.23, close to its 52-week high of
Cantor Fitzgerald Believes ACADIA Pharmaceuticals (NASDAQ: ACAD) Still Has Room to Grow
In a report released today, Charles Duncan from Cantor Fitzgerald reiterated a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $63.00. The company’s shares closed last Thursday at $49.34, close to its 52-week high
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (NASDAQ: ACAD), Globus Medical (NYSE: GMED) and Zynerba Pharmaceuticals (NASDAQ: ZYNE)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on ACADIA Pharmaceuticals (ACAD – Research Report), Globus Medical (GMED – Research Report) and Zynerba Pharmaceuticals (ZYNE – Research Report). ACADIA Pharmaceuticals (ACAD) Needham analyst Alan
ACADIA Pharmaceuticals (ACAD) Gets a Buy Rating from Cowen & Co.
Cowen & Co. analyst Ritu Baral maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) yesterday and set a price target of $66.00. The company’s shares closed last Monday at $44.53. According to TipRanks.com, Baral is a 5-star
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (NASDAQ: ACAD), Tilray (NASDAQ: TLRY) and Aimmune Therapeutics (NASDAQ: AIMT)
Analysts fell to the sidelines weighing in on ACADIA Pharmaceuticals (ACAD – Research Report), Tilray (TLRY – Research Report) and Aimmune Therapeutics (AIMT – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the
Saturday’s Midday Movers: Invivo Therapeutics Holdings (NVIV), Clovis Oncology (CLVS), ACADIA Pharmaceuticals (ACAD), Continental Resources (CLR), Bluebird Bio (BLUE)
So far Saturday, February 29, NASDAQ is up 13.13% and the S&P is up 7.56%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Invivo Therapeutics Holdings (NVIV – Research Report), Clovis Oncology (CLVS
